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OBJECTIVE — Acutehyperglycemiaonadmissionforacutecoronarysyndromeworsensthe
prognosis in patients with and without known diabetes. Postulated mechanisms of this obser-
vation include prothrombotic effects. The aim of this study was to evaluate the effect of elevated
glucose levels on blood clotting in acute coronary syndrome patients.
RESEARCH DESIGN AND METHODS — We studied 60 acute coronary syndrome
patients within the ﬁrst 12 h after pain onset, including 20 subjects with type 2 diabetes, 20
subjects with no diagnosed diabetes but with glucose levels 7.0 mmol/l, and 20 subjects with
glucose levels 7.0 mmol/l. We determined generation of thrombin-antithrombin complexes
(TATs) and soluble CD40 ligand (sCD40L), a platelet activation marker, at the site of microvas-
cular injury, together with ex vivo plasma ﬁbrin clot permeability and lysis time.
RESULTS — The acute coronary syndrome patients with no prior diabetes but elevated glu-
cose levels had increased maximum rates of formation and total production of TATs (by 42.9%,
P  0.0001, and by 25%, P  0.0001, respectively) as well as sCD40L release (by 16.2%, P 
0.0011, and by 16.3%, P  0.0001, respectively) compared with those with normoglycemia,
whereas diabetic patients had the highest values of TATs and sCD40L variables (P  0.0001 for
all comparisons). Patients with hyperglycemia, with no previously diagnosed diabetes, had
longer clot lysis time (by 18%, P  0.0001) similar to that in diabetic subjects, but not lower
clot permeability compared with that in normoglycemic subjects.
CONCLUSIONS — Hyperglycemiainacutecoronarysyndromeisassociatedwithenhanced
local thrombin generation and platelet activation, as well as unfavorably altered clot features in
patients with and without a previous history of diabetes.
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cute hyperglycemia occurs in up to
50% of all ST-segment elevation
myocardialinfarctions,whereaspa-
tients with diabetes represent 25% of
patients with ST-segment elevation myo-
cardial infarctions (1). When glucose tol-
erance testing is performed, 65% of
patients with myocardial infarction and a
negative history of diabetes can be diag-
nosed with diabetes or impaired glucose
tolerance(2).Acutehyperglycemiaonad-
mission has been reported to worsen the
prognosis in myocardial infarction pa-
tients with and without known diabetes
(3), including increased risk of in-
hospital mortality in both groups (4).
Cardiovascular stress induces release
of catecholamines, cortisol, and gluca-
gons, leading to increases in glucose and
free fatty acids that enhance hepatic glu-
coneogenesis and diminish peripheral
glucose uptake. Unfavorable effects of
high blood glucose levels in myocardial
infarction involve impaired left ventricu-
lar function, increased incidence of the
no-reﬂow phenomenon, and a tendency
for arrhythmias (5). Several mechanisms
implicated in the detrimental impact of
hyperglycemia during acute myocardial
ischemia have been postulated, i.e., en-
hanced oxidative stress, the activation of
blood coagulation and platelets, stimula-
tion of inﬂammation, and endothelial cell
dysfunction (5). All of these have also
been reported in type 2 diabetes (6,7).
Evidence for the prothrombotic effects
ofacutehyperglycemiainvivoisscanty.Ex-
posure to 24-h selective hyperglycemia in
healthy volunteers results in increased tis-
sue factor procoagulant activity (8). Acute
hyperglycemia activates platelet aggrega-
tion, enhances thrombin generation, and
activates coagulation factor VII (9). It is not
known whether acute hyperglycemia dur-
ing myocardial infarction is potent enough
to inﬂuence hemostasis. Moreover, hyper-
glycemia, both in diabetic patients and un-
der in vitro conditions, is linked to
unfavorably altered ﬁbrin clot properties
andreducedﬁbrinolysiscomparedwiththe
resultsatnormoglycemia(10,11).Recently,
we have showed that in patients with acute
myocardial infarction, a history of type 2
diabetes is associated with impaired plasma
clot permeability and ﬁbrinolysis (12). The
effectofhyperglycemiaonclotpropertiesin
acute myocardial infarction patients with
no history of diabetes has not been investi-
gated yet. The aim of the study was to
evaluate potential prothrombotic alter-
ations in acute myocardial infarction pa-
tients in relation to hyperglycemia,
including thrombin formation, platelet ac-
tivation, and ﬁbrin network structure/
function.
RESEARCH DESIGN AND
METHODS— Patients with acute
myocardialinfarctionadmittedtothecor-
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the onset of chest pain were enrolled in
the study. We recruited 20 consecutive
acute myocardial infarction patients with
a history of type 2 diabetes, who self-
reportedtakinginsulinororalhypoglyce-
mic drugs on a regular basis (the DM
group) and 20 patients with a negative
history of diabetes, who had a serum glu-
coselevelof7mmol/lonadmission(the
HG group). Twenty patients with glucose
levels 7 mmol/l (the NG group) served
as a reference group.
Inclusion criteria were typical chest
pain and elevated cardiac troponin levels.
Changes in electrocardiogram (ECG) re-
cordingssuchaseitherST-segmenteleva-
tion 0.1 mV or ST-segment depression
0.1 mV in at least two contiguous ECG
leads or normal ECG results were al-
lowed. Exclusion criteria were as follows:
cardiogenic shock, any acute illness, can-
cer,hepaticorrenaldysfunction,ahistory
of venous thromboembolism or stroke,
anticoagulant therapy, and recent myo-
cardial infarction (within the previous 3
months).Allsubjectsreceived300mgas-
pirin 2–8 h before the study. Major ad-
verse coronary events were recorded
within the ﬁrst 30 days after enrollment.
Allsubjectsenrolledinthestudypro-
vided written, informed consent. The
Universityethicscommitteeapprovedthe
study.
Laboratory investigations
Blood samples were obtained from an an-
tecubital vein using a 21-gauge butterﬂy
needle within 15 min upon admission.
The lipid proﬁle, C-reactive protein
(CRP), glucose, creatinine, platelet count,
and cardiac troponin T were determined
using routine laboratory methods. A1C
was analyzed by high-performance liquid
chromatography using a Variant II ana-
lyzer (Bio-Rad, Hercules, CA). A human-
speciﬁc radioimmunoassay kit (Linco
Research, St. Charles, MO) was used to
measure plasma insulin levels. Fibrino-
gen was determined using the Clauss
method. High-sensitivity CRP was mea-
sured by latex nephelometry (Dade Be-
hring, Marburg, Germany). Blood
samples for thrombin and platelet mark-
erswerecentrifugedat2,500gfor15min,
and plasma was stored at 80°C. Using
commercially available enzyme-linked
immunosorbent assays, we determined
the following in plasma: interleukin-6
(IL-6) (R&D Systems, Abingdon, U.K.);
thrombin-antithrombin complexes
(TATs) and prothrombin 1.2 fragments
(F1.2), markers of thrombin formation
(Enzygnost, Dade Behring); and soluble
CD40ligand(sCD40L),amarkerofplate-
let activation (R&D Systems). Routine
laboratory data and hemostatic variables
were also obtained after 30 days from the
event.
Model of vascular injury
Measurements were performed in blood
collected at 60-s intervals from a stan-
dardizedskinincision,madeusingaSim-
plate IR device (Organon Teknika,
Durham, NC) at the inﬂation of the
sphygmomanometer cuff at 40 mmHg, as
described previously (13–15). Blood was
collected by means of heparinized tubes
(Kabe Labortechnik, Numbrecht-
Elsenroth, Germany) into Eppendorf
tubes containing anticoagulants as de-
scribed previously (14,15). After centrif-
ugation at 3,000g at 4°C for 20 min,
supernatants were frozen at 80°C. Both
TAT (Dade Behring) and sCD40L (R&D
Systems) were measured in the samples.
Interassay and intra-assay coefﬁcients of
variation (CVs) were 5–7%. Thrombin
formationandplateletactivationwerede-
scribedasmaximumvelocityofbothpro-
cesses and total amounts of each marker
produced within the ﬁrst 6 min of bleed-
ing (using the trapezoid rule) (14,15).
Clot permeability
Permeation properties of ﬁbrin clots were
assessed according to the method of Mills
et al. (16). Brieﬂy, tubes containing
plasmaclotsformeduponadditionofcal-
cium chloride and human thrombin
(Sigma)wereconnectedviaplastictubing
to a reservoir of 0.05 mol/l Tris-HCl, and
its volume ﬂowing through the gels was
measured within 60 min. A permeation
coefﬁcient (Ks), which indicates the pore
size, was calculated from the equation, as
described (16). The interassay CV was
9.2%.
Plasma clot lysis assay
To determine lysis time, we used an assay
by Lisman et al. (17) with some modiﬁca-
tions. Brieﬂy, citrated plasma was mixed
(1:1) with HEPES buffer containing cal-
cium chloride, diluted recombinant tis-
sue factor (Innovin, Dade Behring),
phospholipid vesicles, and recombinant
tissue plasminogen activator (Boehringer
Ingelheim). The turbidity of this mixture
(100l)wasmeasuredat405nmat37°C
in a SpectraMax 340 kinetic microplate
reader (Molecular Devices). Clot lysis
time was deﬁned as the time from the
midpointofthebaselinetomaximumtur-
bid transition, to the ﬁnal plateau phase.
The interassay and intra-assay CVs were
8.1 and 6.2%, respectively.
Statistical analysis
The study was powered to have an 80%
chance of detecting a 10% intergroup dif-
ference in maximum rate of TAT genera-
tion at the site of microvascular injury
using a P value of 0.05, based on mean
values in published articles (13–15). To
demonstrate such a difference or greater,
12 patients were required in each group.
Thecorrespondingnumberofpatientsfor
local sCD40L release was calculated to be
12.
Continuous data are presented as
means  SD or as median (interquartile
range). The Kolmogorov-Smirnov test
was used to determine normal distribu-
tion. The signiﬁcance of between-group
differences was tested by ANOVA with
Scheffe’s adjustment. Post hoc compari-
sons were made using a Tukey test. The

2 test or Fisher’s exact test was used to
compare categorical variables. Pearson’s
correlations were used to identify associ-
ations between variables. A two-sided P
value  0.05 was considered statistically
signiﬁcant.
RESULTS— The three myocardial in-
farction groups did not differ with regard
todemographicandclinicalvariables(Ta-
ble 1). All three patient groups were en-
rolledafter5.20.3hofchestpainonset
(P  0.9). Patients with diabetes were
treatedeitherwithinsulin(n8;40%)or
with oral hypoglycemic agents (n  12;
60%). Duration of the disease ranged
from 0.5 to 11 (median 5) years. As ex-
pected,glucoselevelswerehigherinboth
hyperglycemic groups and in patients
with normoglycemia, whereas serum in-
sulin and A1C were elevated in the DM
group,withnodifferencebetweentheHG
and NG groups (Table 1). Higher cardiac
troponinTwasobservedintheDMgroup
than in the HG group (Table 1). In con-
trast to CRP, IL-6 levels were elevated by
86%bothintheDMandHGgroupscom-
paredwiththeNGgroup.Fibrinogenlev-
els were 29% higher in the DM group
than in the NG group, with similar values
in both hyperglycemic groups (Table 1).
Bleeding time did not differ among
the three groups (Table 1). The total vol-
ume of blood collected from wounds was
similar in all groups (data not shown).
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Plasma TAT and F1.2 concentrations did
not differ between the DM and HG
groups. However, diabetic patients with
acutemyocardialinfarction,butnotthose
from the HG group, had higher plasma
levels of F1.2 (by 27.5%) and TATs (by
30%) than those observed in the NG
group (Table 1).
TimecoursesofTATgenerationatthe
siteofinjuryweresimilarregardlessofthe
presence or absence of hyperglycemia
(Fig. 1A). Maximum TAT levels were
found at 6 min, with the highest values in
the DM group (112.6  10.4 nmol/l) and
the lowest in the NG group (89.7  9.1
nmol/l; P  0.006). There was no differ-
ence between maximum TAT levels in
bleeding time blood in the HG (96.1 
5.9 nmol/l) and NG groups (P  0.3). A
peak rate of TAT formation after vascular
injury was higher in hyperglycemia
(0.360.03fortheDMgroupand0.3
0.03 nmol/l/s for the HG group, respec-
tively) compared with patients with nor-
moglycemia (0.21  0.03 nmol/l/s; P 
0.0001 for both comparisons). However,
TAT was also generated faster in the DM
group than in the HG group (P 
0.0001). Total amounts generated after
injury within 6 min were increased by
24.3% in diabetic patients with acute
myocardial infarction compared with
amounts in those with elevated glucose
levels without a history of diabetes (P 
0.0001) as well as by 55.4% compared
with amounts in those with normoglyce-
mia during acute myocardial infarction
(P  0.0001) (Fig. 2A of the online ap-
pendix [available at http://dx.doi.org/
10.2337/dc08-0282]).
None of the variables describing TAT
formation at the site of vascular injury
showed associations with plasma TAT
levels, glycemia, insulinemia, age, or
other clinical or laboratory variables in
the three groups studied. Total formation
of TATs within the ﬁrst 6 min was associ-
ated with triglycerides in the HG group,
butnotintheothertwogroups(r0.48;
P  0.03). The maximum rate of TAT
generation and TAT levels tended to be
higherinpatientswhosebloodwasdrawn
afteralongertimefrompainonsetonlyin
the DM group (r  0.38; P  0.1 for
both). Other variables showed no corre-
lationwithtimefrompainonset(datanot
shown).
Platelet activation
Plasma sCD40L levels were similar in the
DM and HG groups. Compared with the
normoglycemic patients, patients in both
the DM and HG groups displayed higher
plasma sCD40L levels by 120 and 82.5%,
respectively (Table 1). Proﬁles of sCD40L
release, reﬂected in its levels in blood ob-
tained from bleeding time wounds,
sharedcommonkineticsinacutemyocar-
Table1—Comparisonsoflaboratoryvariablesinthethreegroupsofpatientswithacutecoronarysyndrome,basedonahistoryofdiabetesand
glucose levels on admission
DM group HG group P value NG group P value* P value†
n 20 20 20
Age (years) 61  10 60  9N S 6 1  7N S N S
Men 14 (70) 16 (80) NS 11 (55) NS NS
STEMI 11 (55) 11 (55) NS 12 (60) NS NS
Hypertension 14 (70) 13 (65) NS 14 (70) NS NS
Previous PCI 9 (45) 4 (20) NS 7 (35) NS NS
Current smokers 14 (70) 13 (65) NS 14 (70) NS NS
Hypoglycemic drugs 20 (100) 0 (0) 0.0001 0 (0) 0.0001 NS
Statins 16 (80) 5 (25) 0.0002 11 (55) NS NS
	-Blockers 17 (85) 16 (80) NS 16 (80) NS NS
ACEIs 15 (75) 11 (55) NS 14 (70) NS NS
Aspirin 20 (100) 20 (100) NS 20 (100) NS NS
Diuretics 8 (40) 6 (30) NS 7 (35) NS NS
Glucose (mmol/l) 9.74  2.34 8.58  0.87 NS 4.69  0.68 0.0001 0.0001
Platelets (10
3/mm
3) 258.9  49.3 249.5  45.8 NS 253.5  41.0 NS NS
CRP (mg/l) 2.72 (0.9–6.5) 1.45 (0.77–4.11) NS 1.9 (1.01–2.32) NS NS
IL-6 (ng/ml) 3.13  1.19 3.13  1.06 NS 1.68  0.56 0.0001 0.0001
TnT (ng/ml) 2.98  2.07 1.53  1.42 0.028 2.92  2.7 NS NS
TnT max (ng/ml) 5.9 (2.7–13.2) 28.9 (5.9–49.7) 0.019 24.9 (7.5–41.9) 0.013 NS
Fibrinogen (g/l) 4.1  1.08 3.17  0.8 0.004 3.04  0.7 0.002 NS
TC (mmol/l) 6.06  1.08 5.42  0.99 NS 5.42  1.14 NS NS
LDL cholesterol (mmol/l) 3.75  1.06 3.31  0.73 NS 3.41  0.99 NS NS
HDL cholesterol (mmol/l) 1.28  0.7 1.21  0.37 NS 1.23  0.15 NS NS
TGs (mmol/l) 1.97  1.46 1.68  1.06 NS 1.56  0.44 NS NS
sCD40L (pg/ml) 747.75  283.72 619.95  306.55 NS 339.75  92.97 0.0001 0.0003
TAT (g/l) 6.58  1.67 5.86  1.73 NS 5.06  1.84 0.0095 NS
F1.2 (nmol/l) 1.16 (0.97–1.89) 1.04 (0.88–1.19) NS 0.91 (0.78–1.13) 0.016 NS
A1C (%) 6.81  0.37 5.5  0.36 0.0001 5.47  0.27 0.0001 NS
Insulin (pmol/l) 154.985  53.47 96.825  31.12 0.0002 86.7  31.15 0.0001 NS
Data are means  SD, n (%), or median (interquartile range). *Comparison (ANOVA, post hoc analysis) between the group of patients with diabetes and that with
glucose levels 7.0 mmol/l (the NG group). †Comparison (ANOVA, post hoc analysis) between the group with no known history of diabetes, but elevated glucose
levels on admission for an acute event (the HG group), and the group with glucose levels 7.0 mmol/l (the NG group). ACEI, angiotensin-converting enzyme
inhibitor; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TnT, cardiac troponin T; TC, total cholesterol; TG, triglyceride.
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increaseindiabeticsubjects(Fig.1B).The
highest local sCD40L value of 23.4  2.6
ng/ml was observed in the DM group. A
lower maximum sCD40L level of 20.3 
1.9 ng/ml (P  0.001) was found in the
HG group. Maximum rates of sCD40L re-
lease were higher in patients in the DM
(0.087  0.009 ng   ml
1   s
1) and HG
(0.086  0.01 ng   ml
1   s
1) groups
than in individuals with normoglycemia
(0.0740.012ng ml
1 s
1;P0.001
for both comparisons). There was no dif-
ference in this variable between the DM
and HG groups (P  0.2). The velocity of
the sCD40L increase in shed blood was
increasedintheHGgroupcomparedwith
that in the NG group (P  0.011).
Total release of sCD40L within the
ﬁrst 6 min was similar in the DM and HG
groups. Both of these groups were char-
acterized by increased amounts of
sCD40L measured after injury (by 28 and
16.3%, P  0.001, respectively) com-
pared with the NG group (Fig. 2B of the
online appendix).
In the DM group, the maximum rate
of the sCD40L release showed no associ-
ation with the duration of diabetes, insu-
linadministration,age,orotherclinicalor
laboratory variables with two exceptions.
It was correlated with glucose (r  0.56;
P  0.01) and with plasma TAT levels
(r  0.53; P  0.02). No similar associa-
tions were observed in the two other
groups. Total release of sCD40L within
the ﬁrst 6 min was associated with total
cholesterol (r  0.47; P  0.036) and
plasma sCD40L levels (r  0.48; P 
0.03)butonlyintheHGgroup.Variables
describing local sCD40L release showed
no signiﬁcant correlations with time from
pain onset (data not shown).
Clot permeability
Lower clot permeability was found in pa-
tients with a prior history of diabetes
compared with subjects from both the
HG and NG groups (Table 2). However,
Ks was similar in the HG and NG groups.
Ks was correlated with ﬁbrinogen in all
Figure 1— Thrombin formation and platelet activation at the site of microvascular injury in
patientswithacutecoronarysyndrome.A:ConcentrationsofTATsinthe60-sbleedingtimeblood
samples in 20 patients with documented diabetes (F), 20 patients with no history of diabetes but
elevated glucose levels (E), and 20 patients with normoglycemia during the acute event (Œ). B:
Concentrations of sCD40L in the 60-s bleeding time blood samples in 20 patients with diabetes
(F), 20 patients with no history of diabetes but elevated glucose levels (E), and 20 patients with
normoglycemia during the acute event (Œ). Values are plotted as means  SEM.
Table 2—Fibrin clot permeability (Ks) and lysis time (t) in the three groups of patients with acute coronary syndrome, based on a history of
diabetes and glucose levels on admission
DM group HG group P value NG group P value* P value†
n 20 20 20
Ks (10
9 cm
2) 6.1 (5.3–7.9) 7.5 (6.9–8.9) 0.02 7.6 (7.1–9.1) 0.006 NS
t (min) 127.9 (98.3–137.4) 116.1 (77.9–120.3) 0.001 98.5 (73.4–111) 0.0001 0.0001
Data are median (interquartile range). *Comparison between the DM and NG groups. †Comparison between the HG and NG groups.
Undas and Associates
DIABETES CARE, VOLUME 31, NUMBER 8, AUGUST 2008 1593groups (r from 0.36 to 0.51; P 
0.05). Ks was inversely associated with
CRP only in the DM group (r  0.42,
P  0.03), but showed no associations
withlipidsorthrombinorplateletparam-
eters in venous or bleeding time blood in
either group.
Fibrinolysis
Clot lysis time was the longest in the dia-
betic patients admitted for acute myocar-
dial infarction and was signiﬁcantly
shorter in the HG group than in subjects
withnormoglycemia(Table2).Lysistime
showed correlations only with CRP in all
three groups (r from 0.35 to 0.49; P 
0.05). No associations between lysis time
and glucose or insulin levels were ob-
served in any of the groups. There were
no correlations of lysis time with throm-
bingenerationorplateletactivationinany
of the patients and in the three groups or
with time from the onset of myocardial
infarction symptoms or troponin levels
(data not shown).
Short-term outcomes
During a 30-day follow-up, there were
three cardiovascular deaths (two in the
DM group and one in the NG group). Re-
current myocardial ischemia was ob-
served in six patients, two in each group.
No intergroup differences in major ad-
verse cardiovascular events were ob-
served. Glucose levels determined 1
month after enrollment revealed that all
normoglycemic subjects had still normo-
glycemia,whereasthreesubjectsfromthe
HG group had glycemia 7 mmol/l; ex-
clusion of these patients did not alter the
results for hemostatic variables (data not
shown).
CONCLUSIONS — Thecurrentstudy
shows that elevated glucose levels are asso-
ciated with signiﬁcantly augmented throm-
binformationandplateletproteinsecretion
in response to vascular injury not only in
patients with type 2 diabetes but also in
those with no prior history of diabetes and
hyperglycemia during acute myocardial in-
farction. Moreover, we demonstrated that
hyperglycemia observed in acute myocar-
dial infarction results in hypoﬁbrinolysis,
regardless of a history of type 2 diabetes,
whereas reduced clot permeability was
foundonlyinpatientswithpreviouslydiag-
noseddiabetescomparedwithnormoglyce-
mic individuals. Our ﬁndings indicate that
not only diabetes but also hyperglycemia
occurringinacutemyocardialinfarctionpa-
tients with no prior diagnosis of diabetes
produces several prothrombotic effects that
may contribute to an increased risk for
thrombotic complications after an acute
coronary event. The impact of hyperglyce-
mia in myocardial infarction patients ap-
peared potent enough to be detected
despite strong prothrombotic effects of cor-
onary plaque injury during myocardial in-
farction.Ourﬁndingsmayalsohelpexplain
a recent observation that glucose-insulin-
potassium therapy, resulting in increased
glucose levels, could be harmful within the
ﬁrst days of acute myocardial infarction
(18).
Because efﬁcient hemostasis occurs
only at vascular lesions where tissue fac-
tor is exposed and platelets rapidly aggre-
gate, measurements of hemostatic
markers at the site of vascular injury are
moresensitivethanthoseinvenousblood
in the assessment of local thrombotic re-
actions (13,14,19). We did not observe
elevated levels of thrombin or platelet
markers in venous blood in diabetic pa-
tients compared with those from the HG
group; the differences were detectable at
the site of injury. Probable mechanisms
for this effect of hyperglycemia involve
enhanced activation of proinﬂammatory
transcription factors that can increase tis-
suefactorexpression(20).Augmentedlo-
cal thrombin production in myocardial
infarction patients with glucose 7.0
mmol/l was accompanied by increased
platelet activation, reﬂected by elevated
sCD40L levels in venous plasma and
bleeding time blood. Of several soluble
platelet activation markers, including
	-thromboglobulin or P-selectin,
sCD40L has been extensively studied in
hyperglycemic subjects (8,9,21) and
measured at the site of injury (19,22);
95% of circulating sCD40L is platelet-
derived (11,23). For these reasons,
sCD40L was chosen as the platelet activa-
tion marker in the current study. Impor-
tantly, a similar increase in sCD40L
release correlated with thrombin forma-
tionhasbeenreportedinpatientswiththe
metabolic syndrome (24).
Fibrin clot analysis revealed reduced
lysis time in the DM and HG groups com-
pared with that in subjects with glycemia
7 mmol/l, without any intergroup dif-
ferences in clot permeability except for
signiﬁcantly higher permeability in dia-
beticsubjects.Glycationoftheﬁbrinogen
molecules is largely responsible for al-
tered ﬁbrin clot features found at elevated
glucose levels (10,11). We extended pre-
vious observations by showing a potent
impact of diabetes on ﬁbrin properties,
easily detectable also in myocardial in-
farctionpatientsdespitethefactthatacute
myocardial ischemia itself is associated
with deleterious clot alterations similar to
those described in diabetic patients (12).
A short-term increase in glucose levels
does not modify ﬁbrin structure, which
explains the similar permeability ob-
served in the HG and NG groups. Re-
duced lysis efﬁciency in the HG and DM
groups indicates the presence of some
glucose-mediated rapid mechanisms im-
pairing ﬁbrinolysis even if the extent of
glycation is negligible. This effect could
be explained by elevated plasminogen ac-
tivator inhibitor 1 observed in hypergly-
cemia (5,6). It might be speculated that
altered ﬁbrin in hyperglycemia leads to
lower binding afﬁnity of both tissue plas-
minogen activator and plasminogen to-
ward ﬁbrin (11) and, as a consequence,
impaired clot lysis in our assay.
Onemightsuspectthatinsulinororal
hypoglycemic agents taken only by dia-
betic patients confounded the data inter-
pretation. However, there is no evidence
that in myocardial infarction patients
such therapy alters thrombin formation
or platelet activation. In terms of ﬁbrin-
modifying properties, insulin, gliclazide,
and metformin have been shown to en-
hance clot lysis (25). We might speculate
thatsusceptibilitytolysisisprobablyeven
weakerinuntreateddiabeticpatientswith
myocardial infarction. Another potential
effect could be mediated by statins that
were taken by a signiﬁcantly lower per-
centage of the HG group before myocar-
dial infarction. Because statins can reduce
thrombin generation (13) and platelet ac-
tivation(20)afterinjuryinstablepatients,
both processes may have been relatively
more vigorous in the HG group than in
theDMandNGgroups.However,nodata
support the view that statins are potent
enoughtosuppressthemassiveactivation
of hemostasis observed in patients with
acute myocardial infarction (26).
This study has limitations. First, the
number of patients studied is limited.
However, we matched the myocardial in-
farction patients with and without ele-
vated glucose levels as well as those with
normoglycemia well. Second, our analy-
sis was based on a determination of each
variable at a single time point. Third, re-
sults of oral glucose tests after myocardial
infarction were not analyzed. However,
lack of signiﬁcant differences in A1C be-
tween the HG and NG groups speaks
against the possibility that patients with
undiagnosed diabetes before the acute
Prothrombotic effects of hyperglycemia
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nally, statistical associations reported
here do not necessarily mean cause-effect
relationships. Further studies are needed
to elucidate this issue.
In summary, our ﬁndings demon-
strate that acute hyperglycemia in acute
myocardial infarction patients without a
previous history of diabetes is associated
with increased thrombin generation and
platelet activation at the site of vascular
injuryaswellasgreaterresistancetoﬁbri-
nolysis. This study provides further in-
sights into the relationship between
hyperglycemia and thrombosis in myo-
cardial infarction patients.
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